Safety and efficacy of a novel nonablative 1,550 nm fractional laser for the treatment of facial dermatological conditions in Republic of Korea: retrospective clinical study
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: Nonablative fractional lasers (NAFLs) have been used since the early 2000s for the treatment of facial dermatological conditions. A new-generation 1,550 nm NAFL has recently become commercially available with a novel handpiece and beam technology. The present retrospective study was designed to assess the safety and efficacy of this system in facial dermatological treatment. Methods: Twenty-one informed and consenting subjects were retrospectively selected for the Institutional Review Board (IRB)-approved study from patients attending the Lutronic in-house clinic for facial dermatological treatments, comprising 15 males and 6 females, average age 39.65 years (range 18-75 years). Fitzpatrick skin types I (1), III (9), and IV (11). The study was approved by the IRB of the Lutronic in-house clinic. Subjects received three treatment sessions with the NAFL system at 4-6-week intervals. Digital clinical photography was obtained at baseline and 12 weeks after final treatment. Two independent dermatologists correctly identified baseline and follow-up images and scored improvement using five-point Global Assessment Improvement Scale (GAIS). Patient satisfaction was scored on 11-point visual analogue scale. Any unexpected adverse events during or after treatment were noted. Results: All patients completed the study and follow-up. Baseline and follow-up images were correctly identified by independent investigators, and the average GAIS score was 3.05 (2-4). Patients were ‘satisfied’ to ‘extremely satisfied’ with treatment, satisfaction scores ranging from 7 to 9, with a patient satisfaction index of 79%. Conclusion: The new-generation NAFL proved safe and effective for facial a variety of dermatological conditions, with no adverse events.
Abstract
Background: Nonablative fractional lasers (NAFLs) have been used since the early 2000s for the treatment of facial dermatological conditions. A new-generation 1,550 nm NAFL has recently become commercially available with a novel handpiece and beam technology. The present retrospective study was designed to assess the safety and efficacy of this system in facial dermatological treatment. Methods: Twenty-one informed and consenting subjects were retrospectively selected for the Institutional Review Board (IRB)-approved study from patients attending the Lutronic in-house clinic for facial dermatological treatments, comprising 15 males and 6 females, average age 39.65 years (range 18-75 years). Fitzpatrick skin types I (1), III (9), and IV (11). The study was approved by the IRB of the Lutronic in-house clinic. Subjects received three treatment sessions with the NAFL system at 4-6-week intervals. Digital clinical photography was obtained at baseline and 12 weeks after final treatment. Two independent dermatologists correctly identified baseline and follow-up images and scored improvement using five-point Global Assessment Improvement Scale (GAIS). Patient satisfaction was scored on 11-point visual analogue scale. Any unexpected adverse events during or after treatment were noted. Results: All patients completed the study and follow-up. Baseline and follow-up images were correctly identified by independent investigators, and the average GAIS score was 3.05 (2-4). Patients were ‘satisfied’ to ‘extremely satisfied’ with treatment, satisfaction scores ranging from 7 to 9, with a patient satisfaction index of 79%. Conclusion: The new-generation NAFL proved safe and effective for facial a variety of dermatological conditions, with no adverse events.